ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.

Novo Nordisk slashed its spending on TV ads for Wegovy by almost 24% between April and May, from $31.6 million to $24.1 ...

AbbVie ABBV expects to return to robust revenue ... driven by its newer immunology drugs, Skyrizi and Rinvoq. The company successfully launched Skyrizi and Rinvoq across Humira's major indications ...

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

Independent Sens. Bernie Sanders of Vermont and Angus King of Maine have introduced a bill that would ban pharmaceutical ...

ABC delivered the most reach for pharma, thanks to its coverage of the NBA playoffs and world news broadcasts.

AbbVie is a Dividend King with a strong product lineup. Bristol Myers Squibb offers a high dividend yield and has underrated ...

AbbVie (ABBV) continued gains for seven straight sessions of gains, as the stock closed higher Friday. The North ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...